Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Author(s) -
Joseph J. Eron,
Bonaventura Clotet,
J. Durant,
Christine Katlama,
Princy Kumar,
Adriano Lazzarin,
Isabelle PoizotMartin,
Gary Richmond,
Vincent Soriano,
Mounir AitKhaled,
Tamio FUJIWARA,
Jenny Huang,
Sherene Min,
Cindy Vavro,
Jane Yeo,
Sharon Walmsley,
Joseph Cox,
Jacques Reynes,
Philippe Morlat,
Daniel Vittecoq,
J.M. Livrozet,
Pompeyo Viciana Fernández,
José M. Gatell,
Edwin DeJesus,
Jerome DeVente,
Jacob Lalezari,
Lewis McCurdy,
Louis A. Sloan,
Benjamin Young,
Anthony LaMarca,
Trevor Hawkins
Publication year - 2013
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/3fft-xh11
Subject(s) - dolutegravir , raltegravir , human immunodeficiency virus (hiv) , medicine , virology , antiretroviral therapy , viral load
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom